Seagen Inc.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| discovery | ×1.13 | 3 |
Strategy profile
Based on 15 disclosed transactions, Seagen Inc. concentrates its licensing activity in Oncology, Metabolic, and Other. Seagen Inc. pays a 1.37x premium over market median. Their most common deal structure is License, with an average disclosed value of $5.0B. Most recent activity: 2026.
Pipeline coverage & gaps
Seagen Inc. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $488M | $2.5B |
| Collaboration | 4 | $483M | $8.3B |
| Acquisition | 2 | $4.9B | $7.4B |
| Option | 1 | $1.3B | $6.3B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | bispecific immuno-oncology assets | 3SBio | solid tumors | unknown | $1.3B | $6.3B |
| 2026 | SSGJ-707 (PD-1/VEGF bispecific) | 3SBio / Shenyang Sunshine | oncology / immuno-oncology | unknown | $1.2B | $6.2B |
| 2026 | Innovent cancer drugs | Innovent Biologics | cancer | unknown | — | $10.0B |
| 2026 | Undisclosed asset | YaoPharma | — | unknown | $150M | $2.0B |
| 2026 | 12 oncology programs (ADCs and multi-specific antibodies) | Innovent | oncology | unknown | $650M | $10.5B |
| 2026 | 12-program antibody-based oncology collaboration | Innovent Biologics | cancer (multiple indications) | discovery | $650M | $10.5B |
| 2026 | Matrix-M | Novavax | — | unknown | $30M | $530M |
| 2026 | Ecnoglutide | Sciwind Biosciences | type 2 diabetes | unknown | — | $495M |
| 2025 | TCR-antigen mapping platform (rheumatoid arthritis target discovery) | Adaptive Biotechnologies | rheumatoid arthritis | discovery | — | $890M |
| 2025 | YP05002 | Chongqing Pharmaceutical Research Institute Co., Ltd. (Yaoyou Pharmaceutical) | type 2 diabetes, obesity, MASH/NASH, long-term weight management | phase_1 | $150M | $2.1B |
| 2025 | YP05002 | YaoPharma | obesity | phase_1 | $150M | $2.1B |
| 2025 | YP05002 | Chongqing Yao Pharmaceutical Company (YaoPharma) | obesity | phase_1 | $150M | $2.1B |
| 2025 | MET-097i + MET-233i | Metsera, Inc. | obesity | phase_2 | $4.9B | $7.2B |
| 2025 | PF-08634404 (SSGJ-707) | 3SBio | multiple cancers including NSCLC, colorectal cancer, small cell lung cancer, gastroesophageal cancer, hepatocellular carcinoma, urothelial carcinoma, renal cell carcinoma | unknown | $1.3B | $6.0B |
| 2025 | MET-097i | Metsera | obesity | preclinical | — | $7.6B |
How this is computed
For each Seagen Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 7 disclosed deal premiums vs. peer medians. Raw premium 1.367, clamped to [0.7, 1.5].